Home
Corporate
Technology
Products
Partnering
News & Media
Contacts
Press Releases
Publications
News & Media
2012
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
2012
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
2012
Effects of a human compact anti-ErbB2 antibody on prostate cancer.
2012
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
2011
Tribodies: Fab-scFv fusion proteins as a platform to create multi-functional pharmaceuticals.
2011
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
2011
A novel ErbB2 epitope targeted by human antitumor immunoagents.
2010
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.
2010
PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1.
2009
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents.
2009
Human anti-ErbB2 immunoagents-immunoRNases and compact antibodies.
2008
Differential binding of human immunoagents and Herceptin to the ErbB2 receptor
2007
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
2005
CD3xCD28 cross-interating bispecofic antibodies improve tumor cell dependet T-cell activation.
2005
Biological properties of a human compact anti-ErbB2 antibody.
2004
A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.
2004
New Strategies in Polypeptide and Antibody Synthesis.
2004
A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.
Filter by year:
2012
2011
2010
2009
2008
2007
2005
2004